ALNY is having a drug likely approved on March 21.
The drug's already in use for neurological symptoms, it's now asking for approval for cardiac symptoms. The FDA didn't even ask for new data, so it's a shoo-in. So they may approve it early.
The company is a biotech, so it's not a drug company with lots of different drugs on the market. But it's been down recently, but is still high $233. And who knows if an expected drug approval will cause a reaction.